Navigation Links
Newborn screening increases survival outcome for patients with severe combined immunodeficiency
Date:1/27/2011

(WASHINGTON, January 27, 2011) Severe Combined Immunodeficiency (SCID) occurs in just one out of every 50,000 to 100,000 births in the United States, yet it is the most serious primary immunodeficiency disorder.[1] A study published today in Blood, the Journal of the American Society of Hematology (ASH), demonstrates that babies with SCID who are diagnosed at birth and receive a hematopoietic stem cell transplant (HSCT), which is the transplantation of blood-forming stem cells, have significantly improved survival.

SCID is a rare group of genetic disorders characterized by severe abnormalities of the development and function of the immune system due to a defect in the specialized white blood cells that defend the body from infection. Patients with SCID lack almost all immune defenses, are prone to serious, life-threatening infections within the first few months of life, and require major treatment for survival beyond infancy. The most effective treatment for SCID is HSCT from the bone marrow of a healthy person. According to the Immune Deficiency Foundation, if a baby with SCID receives a bone marrow transplant in the first 3.5 months of life, the survival rate can be as high as 94 percent.[2]

"If diagnosed early enough, it is probable that every baby with SCID could be treated, and most likely, cured," said Fabio Candotti, MD, Vice Chair of the ASH Scientific Committee on Immunology and Host Defense and Head of the Disorders of Immunity Section in the Genetics and Molecular Biology Branch of the National Human Genome Research Institute at the National Institutes of Health. "Research that promotes early screening and diagnosis is vital for advancing the idea of universal adoption of testing."

The investigators conducted a retrospective cohort study by comparing the outcomes of 60 babies diagnosed at or before birth (between 1982 and 2010) with the outcomes of their relatives who also had the disorder using information gathered from databases from Great Ormond Street Hospital NHS Trust and Newcastle General Hospital in London, U.K.

Results from the study show that, in comparison to the family member with SCID, babies diagnosed at birth had a significantly decreased number of infections (89 percent versus 17 percent, respectively). Patients in the early-diagnosed group were also transplanted earlier and had a dramatically improved survival outcome following HSCT, regardless of donor match, conditioning regimen (chemotherapy or radiation given immediately prior to a transplant to help eliminate the patient's disease and to suppress immune reactions), or type of SCID.

The study showed that 35.4 percent (17 patients) of the 48 family members with SCID died before HSCT, and among the 31 of them who underwent HSCT, 38.7 percent (12 patients) died after the procedure. In comparison, only one patient in the early-diagnosed group died before HSCT and five patients (8.5 percent) died after HSCT. The transplant survival rate of the early-diagnosed group was 91.5 percent (p<.001) compared to 61.3 percent (p<.001) of their relatives with SCID.

"This is the first study that shows formal comparative data to demonstrate that newborn diagnosis can improve survival in SCID patients, regardless of the type of donor or conditioning regimen used," said H. Bobby Gaspar, MD, PhD, senior author of the study and Professor of Pediatrics and Immunology at University College London (UCL) Institute of Child Health in London, U.K. "There is currently no newborn screening for SCID in the U.K.; the United States is the only country that has started screening for SCID, although only a small number of states are screening at this time. Implementation of newborn screening to more states in the U.S. and in other countries would have a major impact on the outcome of SCID."


'/>"/>

Contact: Lindsey Love
webmaster@hematology.org
202-552-4925
American Society of Hematology
Source:Eurekalert

Related biology news :

1. New method will triple amount of genetic information from newborn blood spot screenings
2. Newborns with low vitamin D levels at increased risk for respiratory infections
3. Allô allô! Moms voice plays special role in activating newborns brain
4. New UCLA study raises questions about genetic testing of newborns
5. Drug that helps adults addicted to opioid drugs also relieves withdrawal symptoms in newborns
6. Vitamin deficiency after weight loss surgery can cause vision loss in newborns
7. When do newborns first feel cold?
8. Bilingual babies: The roots of bilingualism in newborns
9. Researchers work on vaccine to improve immune system in newborns
10. New Web site promotes interoperable newborn screening data
11. Experimental treatment halts hypoxic-ischemic brain injury in newborns
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/15/2016)... York , June 15, 2016 ... new market report titled "Gesture Recognition Market by Application ... Forecast, 2016 - 2024". According to the report, the  ... 11.60 billion in 2015 and is estimated to ... USD 48.56 billion by 2024.  Increasing ...
(Date:6/7/2016)... 7, 2016  Syngrafii Inc. and San Antonio ... that includes integrating Syngrafii,s patented LongPen™ eSignature "Wet" ... collaboration will result in greater convenience for SACU ... while maintaining existing document workflow and compliance requirements. ... Highlights: ...
(Date:6/2/2016)... 2, 2016   The Weather Company , an IBM ... an industry-first capability in which consumers will be able to ... ask questions via voice or text and receive relevant information ... Marketers have long sought an advertising solution that ... be personal, relevant and valuable; and can scale across millions ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... 2016  Liquid Biotech USA ... a Sponsored Research Agreement with The University of ... from cancer patients.  The funding will be used ... with clinical outcomes in cancer patients undergoing a ... be employed to support the design of a ...
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with ... in this eBook by providing practical tips, tools, and strategies for clinical researchers. ...
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
Breaking Biology Technology: